Novel Action of 3,4-DAA ameliorating Acute Liver Allograft Injury

作     者：Department of Infectious Diseases,the Third Affiliated Hospital to Wenzhou Medical College,Rui' an,Zhejiang,325200,China Qing-Feng Sun Ji-Guang Ding Department of infectious diseases,The First Affiliated Hospital to Medical College of Zhejiang University,Hangzhou,Zhejiang,310003,China Ji-Fang Sheng Man-Hua Zhu Jun-Jie Li Zi-Ke Sheng Department of Surgery,The First Affiliated Hospital to Medical College of Zhejiang University,Hangzhou,Zhejiang,310003,China Xiao-Feng Tang 

会议名称：《第四届中国医师协会感染科医师大会暨传染病诊治高峰论坛、浙江省医学会肝病、感染病学学术年会》

会议日期：2011年

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

关 键 词：DAA Novel Action of 3,4-DAA ameliorating Acute Liver Allograft Injury Action 

摘      要：The anti-allergic drug,N-(3,4-dimethoxycinnamonyl) anthranilic acid(3,4-DAA),is a synthetic anthranilic acid derivative that has been used therapeutically in Japan for many *** this study,to investigate the effects of 3,4-DAA in allograft immunorejection model,liver orthotopic transplants were performed using inbred male Dark Agouti donors and Lewis rat recipients(allografts).The levels of indoleamine 2,3-dioxygenases (IDO) enzymic activities in five groups,allografts(control),DMSO-treated group(vehicle control),200 mg/kg/day 3,4-DAA-treated group and 200 mg/kg/day 3,4-DAA+5mg/ml 1-Methyl-D-tryptophan(1-MT)treated group were confirmed by determination of L-kynurenine(L-Kyn) *** serum alanine aminotransferase(ALT) levels in 3,4-DAA-treated rats significantly decreased compared with those in mock and control group while treatment of 1 -MT in allografts led to the opposite *** of 3,4-DAA reduced histological severity of allograft immunorejection,decreased serum levels of cytokines tumor necrosis factor-alpha(TNF-α) and interferon-gamma(IFN-γ),and raised serum levels of interleukin-10(IL-10), suggesting 3,4-DAA has both anti-inflammatory and anti-immunorejection properties through IDO in immune regulation,and may therefore be useful in filling an unmet need,in the treatment of allograft immunorejection.